Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Methotrexate
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Methofill 12.5mg/0.25ml inj pre-filled syringes
1001030U0BGAUBK
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 19 |
|
Zlatal 22.5mg/0.9ml inj pre-filled syringes
0801030P0BEABFF
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 18 |
|
Zlatal 12.5mg/0.5ml inj pre-filled syringes
0801030P0BEAFFJ
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 16 |
|
Methofill 22.5mg/0.45ml inj pre-filled syringes
1001030U0BGAQBM
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 14 |
|
Methotrexate 2.5mg/5ml oral liquid
1001030U0AAAEAE
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 12 |
|
Methotrexate 10mg/5ml oral liquid
1001030U0AAAHAH
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 10 |
|
Methotrexate 27.5mg/0.55ml inj pre-filled disposable devices
1001030U0AABZBZ
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 9 |
|
Metoject 25mg/0.5ml inj pre-filled syringes
1001030U0BEAJBI
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 9 |
|
Methofill 7.5mg/0.15ml inj pre-filled syringes
1001030U0BGAKBE
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 4 |
|
Methotrexate 7.5mg/5ml oral liquid
1001030U0AAAIAI
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 4 |
|
Metoject 15mg/0.3ml inj pre-filled syringes
1001030U0BEAHBG
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 4 |
|
Methotrexate 30mg/0.6ml inj pre-filled syringes
1001030U0AABJBJ
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 3 |
|
Metoject 17.5mg/0.35ml inj pre-filled syringes
1001030U0BEAMBL
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 3 |
|
Metoject 20mg/0.4ml inj pre-filled syringes
1001030U0BEAIBH
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 3 |
|
Methofill 30mg/0.6ml inj pre-filled injector
1001030U0BGAJCA
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2 |
|
Methofill 30mg/0.6ml inj pre-filled syringes
1001030U0BGATBJ
|
Methofill (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2 |
|
Methotrexate 12.5mg/5ml oral liquid
1001030U0AAAKAK
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2 |
|
Methotrexate 20mg/2ml inj pre-filled syringes
1001030U0AABABA
|
Methotrexate (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 2 |
|
Methotrexate 5mg/2ml solution for injection vials
0801030P0AAAIAI
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 2 |
|
Methotrexate 1g/10ml solution for injection vials
0801030P0AACKCK
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 1 |
|
Methotrexate 50mg/2ml solution for injection vials
0801030P0AAANAN
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 1 |
|
Metoject 10mg/0.2ml inj pre-filled syringes
1001030U0BEAGBF
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 1 |
|
Ebetrex 10mg/1ml solution for injection pre-filled syringes
1001030U0BFABBB
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 15mg/1.5ml inj pre-filled syringes
1001030U0BFACBC
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
|
Ebetrex 20mg/1ml solution for injection pre-filled syringes
1001030U0BFAGBS
|
Ebetrex (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.